Rituximab Articles
Global orphan drugs market led by Roche's rituximab
26 February 2013
News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans; India revokes Pegasys patent
5 November 2012
Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab
1 September 2011
Rheumatologists’ uptake of Benlysta will not lead to decline in patient share for immunosuppressant/cytotoxics or for Rituxan through 2013
24 February 2011
Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint
31 January 2011
Sandoz moves forward with development of biosimilar rituximab, Roche’s blockbuster RA drug
11 January 2011
Spectrum Pharma links with Viropro to develop biosimilar of Roche blockbuster drug rituximab; FDA expands use of Roche’s Actemra
6 January 2011
GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019
10 August 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
Switzerland’s Roche eyes up China’s potential
2 March 2010
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Biogen Idec’s Tysabri surpasses $1 billion in 2009 sales; fampridine filed in EU, Canada; development deal with Trillium
13 January 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
Seattle Genetics slumps on stopping dacetuzumab Phase IIb diffuse large B-cell lymphoma trial
6 October 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
MabThera for leukemia OKed in Scotland
8 June 2009
Rituxan submitted to FDA for new CLL uses
28 May 2009
Biogen's 1st-qtr profit jumps 54% to $244M
20 April 2009
Spectrum's 2008 loss halves to $15.5M
3 April 2009
Rituxan fails Ph III lupus nephritis trial
16 March 2009
Roche's MabThera approved for CLL
9 March 2009
Biogen Idec's full-year 2008 sales jump 33%
16 February 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
Rituxan slows joint damage in early RA
12 January 2009
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
Rituxan plus chemo boosts PFS in Ph III CLL trials
15 December 2008
Spectrum and Cell Therapeutics form JV for projected expansion in US sales of Zevalin
8 December 2008
Expanded indication for Cephalon
10 November 2008
Roche presents REFLEX study data for MabThera
3 November 2008
Biogen's 3rd-qtr EPS up 71% on drug sales
3 November 2008
CLARIFICATION: Genzyme's Campath Ph II trial results
27 October 2008
Genzyme's Campath does well in Ph II CLL trial
20 October 2008
Ph III ofatumumab trial in NHL completes recruitment
20 October 2008
Potential new use for rituximab in CLL
13 October 2008
Genentech/Biogen Idec's Rituxan linked to death of RA patient due to PML
22 September 2008
Scotland's NHS backs MabThera, Alimta
15 September 2008
Biogen's 2nd-qtr 2008 revenue up 28%
4 August 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
NICE rejects second-line use of TNF-alpha drugs
28 July 2008
Roche's 1st-half net profit sees downturn
28 July 2008
Stock Commentary - New York week to May 5, 2008
12 May 2008
Rituxan misses Ph II/III endpoint in SLE
5 May 2008
Biogen Idec's 1st-qtr 2008 profit jumps 23%
5 May 2008
"Condemned to a life of misery" by UK's NICE
5 May 2008
CHMP recommends expanded label for Zevalin
31 March 2008
Zevalin follow-up results in 96% remission in NHL
24 March 2008
Stock Commentary - New York week to Feb 25, 2008
3 March 2008
Millennium expands Velcade program in NHL
25 February 2008
FDA Treanda decision expected end-October
25 February 2008
Biogen's 4th-qtr net income climbs 85%
14 February 2008
Roche pipeline includes several potential blockbusters likely to enter Ph III testing
11 February 2008
Patients on rituximab achieve ACR 20 response
4 February 2008
Roche's rituximab boosts PFS in CLL
4 February 2008
NICE changes earlier MabThera appraisal
21 January 2008
Stock Commentary - New York week to Jan 7, 2008
14 January 2008
Seattle Genetics earns $4M Genentech milestone
14 January 2008
Biogen ups 2007 income guide, on sales gains
14 January 2008
Cephalon seeks NHL indication for Treanda
7 January 2008
Roche's MabThera yields strong data in CLL
17 December 2007
Strong Ph III data for Cephalon's Treanda
5 November 2007
Stock Commentary - New York - week to October 15, 2007
22 October 2007
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
